Literature DB >> 10146958

Clinical and economic factors in the selection of drugs for gastroesophageal reflux disease.

C M Bate1, P D Richardson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 10146958     DOI： 10.2165/00019053-199303020-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  8 in total

1.  Open access endoscopy--a nationwide survey of current practice.

Authors:  M G Bramble
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

2.  Open-access upper alimentary endoscopy.

Authors:  M W Gear; S P Wilkinson
Journal:  Br J Hosp Med       Date:  1989-05

3.  Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations.

Authors:  C M Bate; P W Keeling; C O'Morain; S P Wilkinson; D N Foster; R A Mountford; J M Temperley; R F Harvey; D G Thompson; M Davis
Journal:  Gut       Date:  1990-09       Impact factor: 23.059

4.  Epidemiology of oesophageal reflux disease.

Authors:  R C Heading
Journal:  Scand J Gastroenterol Suppl       Date:  1989

Review 5.  Omeprazole. Overview and opinion.

Authors:  S Holt; C W Howden
Journal:  Dig Dis Sci       Date:  1991-04       Impact factor: 3.199

6.  Cost and quality effects of alternative treatments for persistent gastroesophageal reflux disease.

Authors:  A L Hillman; B S Bloom; A M Fendrick; J S Schwartz
Journal:  Arch Intern Med       Date:  1992-07

Review 7.  Diagnosis of gastroesophageal reflux disease.

Authors:  G Stacher; W Weiss
Journal:  Scand J Gastroenterol Suppl       Date:  1989

8.  Esophageal disorders in the etiology and pathophysiology of dyspepsia.

Authors:  M Wienbeck; W Berges
Journal:  Scand J Gastroenterol Suppl       Date:  1985
  8 in total
  5 in total

1.  Health-related quality of life of patients with acute erosive reflux esophagitis.

Authors:  S D Mathias; D O Castell; E P Elkin; M L Matosian
Journal:  Dig Dis Sci       Date:  1996-11       Impact factor: 3.199

Review 2.  Ranitidine: a pharmacoeconomic evaluation of its use in acid-related disorders.

Authors:  J E Frampton; D McTavish
Journal:  Pharmacoeconomics       Date:  1994-07       Impact factor: 4.981

3.  Cross-cultural development and validation of a patient self-administered questionnaire to assess quality of life in upper gastrointestinal disorders: the PAGI-QOL.

Authors:  Christine de la Loge; Elyse Trudeau; Patrick Marquis; Peter Kahrilas; Vincenzo Stanghellini; Nicholas J Talley; Jan Tack; Dennis A Revicki; Anne M Rentz; Dominique Dubois
Journal:  Qual Life Res       Date:  2004-12       Impact factor: 4.147

Review 4.  Functional dyspepsia. Current treatment recommendations.

Authors:  Gerald Holtmann; Nicholas J Talley
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

5.  Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Solo Investigator Group.

Authors:  C M Bate; S N Booth; J P Crowe; R A Mountford; P W Keeling; B Hepworth-Jones; M D Taylor; P D Richardson
Journal:  Gut       Date:  1995-04       Impact factor: 23.059
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.